http://www.newswire.ca/en/releases/archive/September2011/12/c2250.html
More Patients with Type 2 Diabetes Reach HbA[1c] Target with Apidra(R) on top of Lantus(R) Than with Twice-daily Aspart Premixed Insulin
- First Randomized Controlled Trial to Show That Basal Plus Regimen Provides more Effective Glycemic Control with Less Hypoglycemia Than with Aspart Premixed Insulin
More Patients with Type 2 Diabetes Reach HbA[1c] Target with Apidra(R) on top of Lantus(R) Than with Twice-daily Aspart Premixed Insulin
- First Randomized Controlled Trial to Show That Basal Plus Regimen Provides more Effective Glycemic Control with Less Hypoglycemia Than with Aspart Premixed Insulin
